Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome

(2020) Ian Miller et al.   JAMA Neurology

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

(2020) Elinor Ben-Menachem et al.   CNS DRUGS

Cytochrome P450 Structure, Function and Clinical Significance: A Review

(2018) Palrasu Manikandan et al.   CURRENT DRUG TARGETS

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Elizabeth A Thiele et al.   LANCET

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

(2018) Orrin Devinsky et al.   NEUROLOGY

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

(2018) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

(2018) Lesley Taylor et al.   CNS DRUGS

Current Treatment Strategies and Future Treatment Options for Dravet Syndrome

(2018) Julie Ziobro et al.   Current Treatment Options in Neurology

Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations

(2017) Philip N. Patsalos et al.   EPILEPSIA

Interactions between cannabidiol and commonly used antiepileptic drugs

(2017) Tyler E. Gaston et al.   EPILEPSIA

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel

(2017) Elaine C. Wirrell et al.   PEDIATRIC NEUROLOGY

Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations

(2017) J. Helen Cross et al.   Frontiers in Neurology

Differential depression of neuronal network activity by midazolam and its main metabolite 1-hydroxymidazolam in cultured neocortical slices

(2017) Monika Balk et al.   Scientific Reports

Treatment of Dravet Syndrome

(2016) Elaine C. Wirrell   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Mortality in Dravet syndrome

(2016) Monica S. Cooper et al.   EPILEPSY RESEARCH

Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials

(2016) Angela W. Dymond et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy

(2015) Alexandra L. Geffrey et al.   EPILEPSIA

Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans

(2015) Alex F. Manini et al.   Journal of Addiction Medicine

Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling

(2015) Vijay V. Upreti et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19

(2013) Rongrong Jiang et al.   Drug Metabolism and Pharmacokinetics

When is Protein Binding Important?*

(2013) Jules Heuberger et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Valproic acid pathway

(2013) Yogita Ghodke-Puranik et al.   Pharmacogenetics and Genomics

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

Dravet syndrome and parent associations: The IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief

(2011) Joan V. Skluzacek et al.   EPILEPSIA

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes

(2011) Rongrong Jiang et al.   LIFE SCIENCES

Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety

(2011) Satoshi Yamaori et al.   LIFE SCIENCES

Treatment of Lennox-Gastaut syndrome: overview and recent findings

(2011) Kenou Rijckevorsel   Neuropsychiatric Disease and Treatment

Metabolism of 1'- and 4-Hydroxymidazolam by Glucuronide Conjugation Is Largely Mediated by UDP-Glucuronosyltransferases 1A4, 2B4, and 2B7

(2010) K.-A. Seo et al.   DRUG METABOLISM AND DISPOSITION

Increased Risk of Death Among Children With Lennox-Gastaut Syndrome and Infantile Spasms

(2009) Andrew R. Autry et al.   JOURNAL OF CHILD NEUROLOGY

Lennox-Gastaut Syndrome (LGS): Development of conceptual models of health-related quality of life (HRQL) for caregivers and children

(2009) Katy Gallop et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol

(2008) KP Kanebratt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS